Vitiligo worsened following the second dose of
            <scp>mRNA SARS‐CoV</scp>
            ‐2 vaccine

Caroppo, Francesca; Deotto, Maria Ludovica; Tartaglia, Jacopo; Fortina, Anna Belloni

doi:10.1111/dth.15434

Cited by 9 publications

(7 citation statements)

References 12 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The systematic review included and analyzed 14 studies. [3][4][5][6][7][8][9][10][11][12][13][14][15][16] We observed hetero- COVID-19 vaccines, regardless of their design, rely on presenting the SARS-CoV-2 spike glycoprotein (SP) antigen to induce immunological memory and neutralizing antibodies. 21 Studies have revealed similarities between fragments of the SARS-CoV-2 SP and mammalian proteins, especially human (Homo sapiens) proteomes.…”

Section: Discussionmentioning

confidence: 99%

COVID‐19 vaccine–associated vitiligo: A cross‐sectional study in a tertiary referral center and systematic review

Tsai

2023

The Journal of Dermatology

View full text Add to dashboard Cite

Vitiligo is an autoimmune skin disorder that occurs due to immunemediated loss of functional melanocytes, leading to patchy skin depigmentation. The triggering of an autoimmune phenomena in patients infected with coronavirus disease 2019 (COVID-19) and those receiving COVID-19 vaccinations has been increasingly reported, and these adverse events have also been seen in vitiligo. Cases of new-onset and exacerbation of vitiligo following COVID-19 vaccination have been reported in individuals of all ages, ethnicities, and with different vaccine types. While current guidelines and consensus recommend COVID-19 vaccination for most patients, including those with autoimmune diseases, 1,2 practitioners must assess the risk and potential for disease onset or flare-up. According to the Taiwan Centers for Disease Control, around 21.7 million people in our population have received at least one primary COVID-19 vaccine, with 94% of them having been vaccinated, while 88% have received at least two doses and 74% have received at least three doses. In light of the emergence of new Delta and Omicron variants, booster vaccination programs are now underway to enhance the humoral response. Some eligible groups can now receive the fourth vaccination booster and a fifth booster dose of Moderna's next-generation bivalent vaccine.Our study aims to report the incidence of vitiligo following primary and booster COVID-19 vaccines. We retrospectively reviewed electronic medical records of new-onset and exacerbations of vitiligo following COVID-19 vaccinations at our vitiligo clinic, which is located at a tertiary referral center. In addition, we conducted a systematic review to analyze the current evidence regarding COVID-19 vaccine-associated vitiligo. | MATERIAL S AND ME THODSWe conducted a retrospective study at our vitiligo clinic, which is located at a Taiwanese tertiary medical center (Chang Gung Memorial Hospital, Linkou, and Taipei branches). The study included patients with new-onset vitiligo or exacerbations of preexisting vitiligo that were diagnosed within a month of receiving COVID-19 vaccination between January 1, 2021, and September 30, 2022. We clinically diagnosed vitiligo based on the presence of acquired amelanotic macules and patches with well-defined margins and typical distribution. Wood's lamp examination was used to identify vitiligo lesions

show abstract

Section: Discussionmentioning

confidence: 99%

COVID‐19 vaccine–associated vitiligo: A cross‐sectional study in a tertiary referral center and systematic review

Tsai

2023

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“… BNT162b2:31 mRNA-1273: 5 AZD1222: 19 Ad26.COV2: 0 Chilblains-like/pernio 12 Russo et al 188 (3), Paparella et al 189 (1), Davido et al 190 (1), Lopez et al 191 (1), Pileri et al 192 (1), Piccolo et al 193 (1), Pérez-López et al 194 (1), Cameli et al 195 (1), Kha et al 196 (1), Lesort et al 197 (1). BNT162b2:9 mRNA-1273: 2 AZD1222: 1 Ad26.COV2: 0 Vitiligo 11 Kaminetsky et al 198 (1), Militello et al 199 (1), Singh et al 200 (1), Nicolaidou et al 201 (1), Flores-Terry et al 202 (1), Bukhari et al 203 (1), Uğurer et al 204 (1), Ciccarese et al 205 (1), López Riquelme et al 206 (1), Okan et al 207 (1), Caroppo et al 208 (1). BNT162b2: 7 mRNA-1273: 3 AZD1222: 1 Ad26.COV2: 0 Abbreviations : BNT162b2, Pfizer mRNABNT162b2; mRNA-1273, Moderna mRNA-1273; AZD1222, AstraZeneca-Oxford AZD1222; Ad26.COV2, Johnson & Johnson Ad26.COV2.S.…”

Section: Methodsmentioning

confidence: 99%

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature

Battista¹,

Marasca²,

Genco³

et al. 2022

CCID

View full text Add to dashboard Cite

The outbreak of coronavirus disease 2019 represented a new worldwide challenge, strongly impacting on the global economy, overall health and lifestyle. Since then, several strategies have been adopted to contain the widespread of infection. Among these, vaccination is currently the most important measure to fight against the pandemic. However, several concerns such as slower-than-hoped-for rollout, the hurried approval with limited data, the mechanism of action (in particular mRNA-based), and the uncertain duration of protection they afforded were initially raised. Moreover, even if cutaneous reactions have been rarely reported in clinical trials, global mass vaccination showed several dermatologic reactions not initially recognized, leaving dermatologists to decide how to diagnose and treat them. In this scenario, dermatologists should be ready to promptly recognize these clinical manifestations. Thus, the aim of this manuscript is to review current literature on cutaneous reactions following COVID-19 vaccination, particularly inflammatory dermatological diseases, in order to help clinicians to better understand these dermatological conditions and to provide an extensive overview of all the vaccine-related skin manifestations.

show abstract

“…[36][37][38] However, vitiligo that is presented as skin depigmentation has also been common after SARS-CoV-2 vaccination including mRNA-1273 (Moderna) vaccine and mRNA BNT162/Comirnaty vaccine (Pfizer-BioNTech). [39][40][41] Most cases of new-onset COVID vaccine-related vitiligo have been reported within 1 week following receiving the first vaccine dose, with progression after the second dose. 39,42 The probability of developing COVID vaccine-related vitiligo is higher in patients with pre-existing autoimmune diseases, such as ulcerative colitis 33 As a matter of fact, the immune system is stimulated by vaccines to produce antibodies.…”

Section: Covid Vaccine-related Vitiligomentioning

confidence: 99%

“…Several cases of hypo pigmentations have been reported after receiving COVID vaccines, resulting from cutaneous reactions such as toxic epidermal necrolysis (TEN), subacute cutaneous lupus erythematosus (SCLE), and pityriasis lichenoides 36–38 . However, vitiligo that is presented as skin depigmentation has also been common after SARS‐CoV‐2 vaccination including mRNA‐1273 (Moderna) vaccine and mRNA BNT162/Comirnaty vaccine (Pfizer‐BioNTech) 39–41 …”

Section: Introductionmentioning

confidence: 99%

Various aspects of the relationship between vitiligo and theCOVID‐19 pandemic orSARS‐CoV‐2 vaccines: Clinical pearls for dermatologists

Aryanian

Balighi

Hatami

et al. 2023

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Vitiligo is a pigmentary disorder that is manifested as the development of pale depigmented patches over any areas of the skin or mucous membrane. It affects 0.5%-2% of the world population. Vitiligo is classified as localized (segmental) or generalized (non-segmental) types. 1 This condition occurs as a result of progressive destruction of skin melanocytes. There are different opinions about the etiopathogenesis of vitiligo; however, no exact explanation has been found. Nevertheless, T-cell autoimmunity and prolonged cytokine release are believed to play an important role. 2

show abstract

Vitiligo worsened following the second dose of mRNA SARS‐CoV ‐2 vaccine

Cited by 9 publications

References 12 publications

COVID‐19 vaccine–associated vitiligo: A cross‐sectional study in a tertiary referral center and systematic review

COVID‐19 vaccine–associated vitiligo: A cross‐sectional study in a tertiary referral center and systematic review

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature

Various aspects of the relationship between vitiligo and theCOVID‐19 pandemic orSARS‐CoV‐2 vaccines: Clinical pearls for dermatologists

Contact Info

Product

Resources

About